Faes Farma SA (FAE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faes Farma SA (FAE) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€35.56 Million ≈ $41.57 Million USD) by net assets (€747.70 Million ≈ $874.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Faes Farma SA - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Faes Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Faes Farma SA (FAE) financial obligations for a breakdown of total debt and financial obligations.
Faes Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faes Farma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tessenderlo
BR:TESB
|
0.070x |
|
Concentrix Corporation
NASDAQ:CNXC
|
-0.030x |
|
Shenzhen MeiG Smart Technology Co Ltd
SHE:002881
|
0.075x |
|
UFP Technologies Inc
NASDAQ:UFPT
|
0.089x |
|
Fair Oaks Income Limited
LSE:FAIR
|
0.168x |
|
Progyny Inc
NASDAQ:PGNY
|
0.105x |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
0.023x |
|
Huabao Flavours & Fragrances Co Ltd Class A
SHE:300741
|
0.014x |
Annual Cash Flow Conversion Efficiency for Faes Farma SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Faes Farma SA from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Faes Farma SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €747.70 Million ≈ $874.14 Million |
€78.49 Million ≈ $91.76 Million |
0.105x | -33.94% |
| 2024-12-31 | €726.62 Million ≈ $849.49 Million |
€115.47 Million ≈ $134.99 Million |
0.159x | +4.40% |
| 2023-12-31 | €663.35 Million ≈ $775.52 Million |
€100.97 Million ≈ $118.04 Million |
0.152x | -14.15% |
| 2022-12-31 | €602.28 Million ≈ $704.13 Million |
€106.79 Million ≈ $124.85 Million |
0.177x | +19.78% |
| 2021-12-31 | €538.07 Million ≈ $629.06 Million |
€79.64 Million ≈ $93.11 Million |
0.148x | -10.82% |
| 2020-12-31 | €472.88 Million ≈ $552.84 Million |
€78.49 Million ≈ $91.76 Million |
0.166x | +1.59% |
| 2019-12-31 | €413.65 Million ≈ $483.60 Million |
€67.58 Million ≈ $79.01 Million |
0.163x | -0.83% |
| 2018-12-31 | €360.15 Million ≈ $421.06 Million |
€59.34 Million ≈ $69.37 Million |
0.165x | +26.65% |
| 2017-12-31 | €320.77 Million ≈ $375.02 Million |
€41.73 Million ≈ $48.78 Million |
0.130x | -25.32% |
| 2016-12-31 | €284.89 Million ≈ $333.06 Million |
€49.62 Million ≈ $58.02 Million |
0.174x | +8.29% |
| 2015-12-31 | €254.34 Million ≈ $297.34 Million |
€40.91 Million ≈ $47.83 Million |
0.161x | +14.00% |
| 2014-12-31 | €228.63 Million ≈ $267.29 Million |
€32.26 Million ≈ $37.71 Million |
0.141x | -11.81% |
| 2013-12-31 | €197.81 Million ≈ $231.26 Million |
€31.65 Million ≈ $37.00 Million |
0.160x | +23.86% |
| 2012-12-31 | €184.82 Million ≈ $216.07 Million |
€23.87 Million ≈ $27.91 Million |
0.129x | +8.38% |
| 2011-12-31 | €167.61 Million ≈ $195.96 Million |
€19.98 Million ≈ $23.35 Million |
0.119x | +29.44% |
| 2010-12-31 | €165.51 Million ≈ $193.50 Million |
€15.24 Million ≈ $17.81 Million |
0.092x | -33.21% |
| 2009-12-31 | €122.93 Million ≈ $143.71 Million |
€16.95 Million ≈ $19.81 Million |
0.138x | -37.03% |
| 2008-12-31 | €156.71 Million ≈ $183.21 Million |
€34.31 Million ≈ $40.11 Million |
0.219x | +153.53% |
| 2007-12-31 | €151.06 Million ≈ $176.60 Million |
€13.04 Million ≈ $15.25 Million |
0.086x | -39.41% |
| 2006-12-31 | €139.85 Million ≈ $163.50 Million |
€19.93 Million ≈ $23.30 Million |
0.143x | +40.54% |
| 2005-12-31 | €131.62 Million ≈ $153.88 Million |
€13.35 Million ≈ $15.60 Million |
0.101x | -- |
About Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants servic… Read more